Hypoactive Sexual Desire Disorder

Indicated for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not caused by a coexisting medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance
100 mg PO once daily at bedtime.Flibanserin hydrochloride powder
Dosed at bedtime because administration during waking hours increases risks of hypotension, syncope, accidental injury, and CNS depression
Discontinued after 8 weeks if no improvement
Missed dose
If a dose is missed at bedtime, instruct the patient to take the next dose at bedtime on the next day
Instruct the patient to not double the next dose
CYP3A4 inhibitors
Coadministration with moderate or strong CYP3A4 inhibitors is contraindicated
If initiating flibanserin following moderate or strong CYP3A4 inhibitor use, start flibanserin 2 weeks after the last dose of the CYP3A4 inhibitor
If initiating a moderate or strong CYP3A4 inhibitor following flibanserin use, start the moderate or strong CYP3A4 inhibitor 2 days after the last dose of flibanserin